International Arbitration of Life Sciences Disputes: Key Issues and Best Practices

International Arbitration of Life Sciences Disputes: Key Issues and Best Practices

Charles River Associates
Speaking Engagement

WilmerHale Partner Rachael Kent will be on a panel titled “Why International Arbitration for Life Sciences Disputes?”

The life sciences industry—pharmaceuticals, medical devices, diagnostics, vaccines and related businesses—is huge, growing and global, with international licensing, sales contracts, research and development agreements and joint ventures.

Each of these international ventures can lead to disputes, and well-positioned life sciences companies prefer international arbitration to litigation as the practical way to achieve confidential, widely enforceable judgments in a neutral setting.

Listen in as a distinguished panel of speakers explain why international arbitration is the preferred dispute resolution mechanism for life sciences disputes, before they take a deeper dive into some of the complex issues that can arise in such disputes. Join the panelist for a reception following the event.

Read More About the Event



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.